ECM
KYTX icon

ExodusPoint Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

ExodusPoint Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$423K Buy
+49,011
New +$408K ﹤0.01% 1232
2024
Q4 		– Sell
-41,984
Closed -$205K – 2150
2024
Q3 		$205K Buy
+41,984
New +$324K ﹤0.01% 1452

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

ExodusPoint Capital Management's KYTX Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 49,011 shares worth $423K. The stake represents ﹤0.01% of the portfolio and ranks #1232 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in KYTX as recently as Q3 2024.

ExodusPoint Capital Management first reported a position in KYTX in Q3 2024 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • ExodusPoint Capital Management held 49,011 shares of Kyverna Therapeutics worth $423K as of Q1 2026.
  • Kyverna Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1232 holding.
  • ExodusPoint Capital Management first reported a position in Kyverna Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.